SV2011003821A - FENANTRENONE COMPOUNDS, COMPOSITIONS AND METHODS - Google Patents
FENANTRENONE COMPOUNDS, COMPOSITIONS AND METHODSInfo
- Publication number
- SV2011003821A SV2011003821A SV2011003821A SV2011003821A SV2011003821A SV 2011003821 A SV2011003821 A SV 2011003821A SV 2011003821 A SV2011003821 A SV 2011003821A SV 2011003821 A SV2011003821 A SV 2011003821A SV 2011003821 A SV2011003821 A SV 2011003821A
- Authority
- SV
- El Salvador
- Prior art keywords
- compounds
- fenantrenone
- compositions
- methods
- salts
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Steroid Compounds (AREA)
- Pyridine Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
COMPUESTOS DE FORMULA I: (VER FORMULA); O SUS SALES, QUE SON MODULADORES DEL RECEPTOR GLUCOCORTICOIDE. LOS COMPUESTOS Y SALES DE LA INVENCIÓN SON ÚTILES EN EL TRATAMIENTO DE AFECCIONES MEDIADAS POR LA ACTIVIDAD DEL RECEPTOR GLUCOCORTICOIDE.FORMULA COMPOUNDS I: (SEE FORMULA); OR ITS SALTS, WHICH ARE GLUCOCORTICOID RECEPTOR MODULATORS. THE COMPOUNDS AND SALTS OF THE INVENTION ARE USEFUL IN THE TREATMENT OF AFFECTIONS MEDIATED BY THE ACTIVITY OF THE GLUCOCORTICOID RECEIVER.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8409508P | 2008-07-28 | 2008-07-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SV2011003821A true SV2011003821A (en) | 2011-07-28 |
Family
ID=41037773
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SV2011003821A SV2011003821A (en) | 2008-07-28 | 2011-01-28 | FENANTRENONE COMPOUNDS, COMPOSITIONS AND METHODS |
Country Status (39)
| Country | Link |
|---|---|
| US (2) | US8148409B2 (en) |
| EP (1) | EP2307375B1 (en) |
| JP (1) | JP4823397B1 (en) |
| KR (1) | KR101377860B1 (en) |
| CN (1) | CN102112446B (en) |
| AP (1) | AP2744A (en) |
| AR (1) | AR072535A1 (en) |
| AU (1) | AU2009278029B2 (en) |
| BR (1) | BRPI0917212A2 (en) |
| CA (1) | CA2729578C (en) |
| CL (1) | CL2011000141A1 (en) |
| CO (1) | CO6290761A2 (en) |
| CR (1) | CR20110012A (en) |
| CU (1) | CU23983B1 (en) |
| DK (1) | DK2307375T3 (en) |
| DO (1) | DOP2011000029A (en) |
| EA (1) | EA018024B1 (en) |
| EC (1) | ECSP11010795A (en) |
| ES (1) | ES2527137T3 (en) |
| GE (1) | GEP20125640B (en) |
| GT (1) | GT201100026A (en) |
| HK (1) | HK1154245A1 (en) |
| HR (1) | HRP20150021T1 (en) |
| IL (1) | IL210492A (en) |
| MA (1) | MA32512B1 (en) |
| MX (1) | MX2011001053A (en) |
| NI (1) | NI201100028A (en) |
| NZ (1) | NZ590559A (en) |
| PE (1) | PE20110559A1 (en) |
| PL (1) | PL2307375T3 (en) |
| PT (1) | PT2307375E (en) |
| RS (1) | RS53747B1 (en) |
| SI (1) | SI2307375T1 (en) |
| SV (1) | SV2011003821A (en) |
| TW (1) | TWI374878B (en) |
| UA (1) | UA99198C2 (en) |
| UY (1) | UY32011A (en) |
| WO (1) | WO2010013158A1 (en) |
| ZA (1) | ZA201101520B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2830234A1 (en) * | 2011-03-15 | 2012-09-20 | Abbvie Inc. | Nuclear hormone receptor modulators |
| TW201422590A (en) | 2012-09-07 | 2014-06-16 | Abbvie Inc | Heterocyclic nuclear hormone receptor modulators |
| EP2935284A4 (en) | 2012-12-21 | 2016-04-27 | Abbvie Inc | Heterocyclic nuclear hormone receptor modulators |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EE05584B1 (en) | 1999-04-30 | 2012-10-15 | Pfizer Products Inc. | Gl corticoid receptor modulators |
| CA2379650C (en) | 1999-07-30 | 2008-09-02 | Eisai Co., Ltd. | Process for producing a basic antibiotic inorganic acid salt, and oxalate intermediate |
| DE60120077T2 (en) | 2000-10-28 | 2006-11-02 | Pfizer Products Inc., Groton | Modulators of the glucocorticoid receptor |
| ES2246292T3 (en) * | 2000-10-30 | 2006-02-16 | Pfizer Products Inc. | GLUCOCORTICOID RECEIVER MODULATORS. |
| SI1521733T1 (en) * | 2002-07-08 | 2014-10-30 | Pfizer Products Inc. | Modulators of the glucocorticoid receptor |
| CN101115761B (en) | 2005-01-19 | 2012-07-18 | 里格尔药品股份有限公司 | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
| GB0613836D0 (en) | 2006-07-13 | 2006-08-23 | Univ Greenwich | New medical use of triazine derivatives |
| DK2078026T3 (en) | 2006-11-21 | 2012-04-30 | Rigel Pharmaceuticals Inc | PRODRUG SALTS OF 2,4-PYRIMIDINE DIAMINE COMPOUNDS AND APPLICATIONS THEREOF |
| WO2008070149A2 (en) | 2006-12-05 | 2008-06-12 | Neurogesx, Inc. | Prodrugs and methods of making and using the same |
| AU2008211622B2 (en) * | 2007-02-02 | 2012-04-19 | Pfizer Products Inc. | Tricyclic compounds and their use as glucocorticoid receptor modulators |
| EP2114970B1 (en) * | 2007-02-02 | 2011-08-03 | Pfizer Products Inc. | Tricyclic compounds and their use as glucocorticoid receptor modulators |
-
2009
- 2009-07-14 AU AU2009278029A patent/AU2009278029B2/en not_active Ceased
- 2009-07-14 CN CN200980129538XA patent/CN102112446B/en not_active Expired - Fee Related
- 2009-07-14 RS RS20150019A patent/RS53747B1/en unknown
- 2009-07-14 PT PT97865927T patent/PT2307375E/en unknown
- 2009-07-14 SI SI200931100T patent/SI2307375T1/en unknown
- 2009-07-14 PE PE2011000098A patent/PE20110559A1/en not_active Application Discontinuation
- 2009-07-14 DK DK09786592.7T patent/DK2307375T3/en active
- 2009-07-14 GE GEAP200912074A patent/GEP20125640B/en unknown
- 2009-07-14 WO PCT/IB2009/053044 patent/WO2010013158A1/en active Application Filing
- 2009-07-14 KR KR1020117002134A patent/KR101377860B1/en not_active IP Right Cessation
- 2009-07-14 ES ES09786592.7T patent/ES2527137T3/en active Active
- 2009-07-14 BR BRPI0917212A patent/BRPI0917212A2/en not_active IP Right Cessation
- 2009-07-14 CA CA2729578A patent/CA2729578C/en not_active Expired - Fee Related
- 2009-07-14 EP EP09786592.7A patent/EP2307375B1/en active Active
- 2009-07-14 JP JP2011520622A patent/JP4823397B1/en not_active Expired - Fee Related
- 2009-07-14 PL PL09786592T patent/PL2307375T3/en unknown
- 2009-07-14 UA UAA201100440A patent/UA99198C2/en unknown
- 2009-07-14 NZ NZ590559A patent/NZ590559A/en not_active IP Right Cessation
- 2009-07-14 MX MX2011001053A patent/MX2011001053A/en active IP Right Grant
- 2009-07-14 EA EA201100080A patent/EA018024B1/en not_active IP Right Cessation
- 2009-07-14 AP AP2011005562A patent/AP2744A/en active
- 2009-07-20 US US12/505,932 patent/US8148409B2/en not_active Expired - Fee Related
- 2009-07-27 AR ARP090102852A patent/AR072535A1/en unknown
- 2009-07-27 TW TW098125265A patent/TWI374878B/en not_active IP Right Cessation
- 2009-07-28 UY UY0001032011A patent/UY32011A/en not_active Application Discontinuation
-
2011
- 2011-01-06 IL IL210492A patent/IL210492A/en not_active IP Right Cessation
- 2011-01-10 CR CR20110012A patent/CR20110012A/en unknown
- 2011-01-21 CL CL2011000141A patent/CL2011000141A1/en unknown
- 2011-01-26 NI NI201100028A patent/NI201100028A/en unknown
- 2011-01-27 GT GT201100026A patent/GT201100026A/en unknown
- 2011-01-27 DO DO2011000029A patent/DOP2011000029A/en unknown
- 2011-01-27 CO CO11009253A patent/CO6290761A2/en active IP Right Grant
- 2011-01-28 SV SV2011003821A patent/SV2011003821A/en unknown
- 2011-01-28 MA MA33568A patent/MA32512B1/en unknown
- 2011-01-28 EC EC2011010795A patent/ECSP11010795A/en unknown
- 2011-01-28 CU CU2011000020A patent/CU23983B1/en active IP Right Grant
- 2011-02-25 ZA ZA2011/01520A patent/ZA201101520B/en unknown
- 2011-08-04 HK HK11108133.8A patent/HK1154245A1/en not_active IP Right Cessation
-
2012
- 2012-02-27 US US13/406,446 patent/US8552035B2/en not_active Expired - Fee Related
-
2015
- 2015-01-09 HR HRP20150021AT patent/HRP20150021T1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SV2009003346A (en) | TRICYCLE COMPOUNDS, COMPOSITIONS AND PROCEDURES. | |
| ECSP11010885A (en) | HETEROARILOS SUBSTITUTED | |
| GT201300164A (en) | BICYCLE DERIVATIVES (3.2.1.) OCTILAMIDA AND ITS USES | |
| EA201590292A1 (en) | COMPOUNDS WHICH ARE SIP-MODULATING AGENTS AND / OR ATX-MODULATING AGENTS | |
| CL2008003159A1 (en) | Compounds derived from substituted diamines, their pharmaceutically acceptable salts or their solvates; intermediate compounds; Useful as antiobesity agents, mediated by the inhibition of the npy y5 receptor. | |
| CL2011003147A1 (en) | Compounds derived from n- (1-4- (1h-pyrazol-5-yl) phthalazine-1-yl) piperidine-4-yl) benzamide; pharmaceutical composition that contains them, useful as antagonist of the hedgehog trajectory, in the treatment of cancer. | |
| CR20120510A (en) | DERIVATIVES OF PIPERIDIN-4-IL AZETIDINE AS INHIBITORS OF JAK1 | |
| CR20110467A (en) | DERIVATIVES OF BENZOFURANILO AS INHIBITORS OF GLUCOQUINASE | |
| EA201490922A1 (en) | HIDANTOIN DERIVATIVES USEFUL AS KV3-CHANNEL INHIBITORS | |
| MA32508B1 (en) | Organic compounds | |
| EA201171063A1 (en) | PHARMACEUTICAL COMPOSITIONS OF OLMESARTAN | |
| ECSP13012893A (en) | ASYMMETRIC UREAS AND MEDICAL USES OF THE SAME | |
| ECSP13012600A (en) | CO-crystals and salts of CCR3 inhibitors | |
| BRPI0814772A2 (en) | INDAZOES REPLACED BY 5-PYRIDINONE | |
| BR112014030474A2 (en) | new bicyclic thiophenylamide compounds | |
| CO6351779A2 (en) | SMALL MOLECULA INHIBITORS OF THE ANDROGEN RECEPTOR N-TERMINAL ACTIVATION | |
| CO6321288A2 (en) | SALES OF HIV INHIBITING COMPOUNDS | |
| CO6341625A2 (en) | DERIVATIVES OF INDOL AS ANTI-CANCER AGENTS | |
| EA200970662A1 (en) | TRICYCLIC COMPOUNDS AND THEIR APPLICATION AS GLUCOCORTICOID RECEPTOR MODULATORS | |
| SV2011003821A (en) | FENANTRENONE COMPOUNDS, COMPOSITIONS AND METHODS | |
| UY32654A (en) | COMPOUNDS 1- (2-RENT-2,3-DIHIDRO-BENZOFURAN-4-IL) -PIRROLIDIN-3-ILAMINOACILO | |
| CY1114207T1 (en) | Benzofuranyl derivatives for use as glucokinase inhibitors | |
| CU20080116A7 (en) | 3-AMINOCICLOPENTANOCARBOXAMIDS AS MUDULATORS OF CHEMIOKIN RECEPTORS |